Boston Scientific Corporation (NYSE: BSX) acquired Obsidio, Inc., a company that has developed the Gel Embolic Material (GEM™) technology used for embolization of blood vessels in the peripheral vasculature.
The amount of the deal was not disclosed. The transaction is expected to be immaterial to Boston Scientific’s GAAP and adjusted earnings per share in 2022.
Embolization is a minimally invasive procedure intended to obstruct or reduce blood flow to an abnormality or tumor to stop hemorrhaging, reduce the size of malignant and benign tumors, and stabilize venous and arterial malformations.
Recently cleared by the U.S. Food and Drug Administration (FDA), the GEM technology is a semi-solid, proprietary material packaged in a ready-to-use form, thus reducing the preparation time required for many embolization procedures. Physicians deliver the GEM agent through a catheter, and its gel-like composition enables controlled placement within patient anatomy. Unlike solid and liquid embolics that can take time to form an obstruction to blood flow, once placed, the GEM technology conforms to the targeted vasculature, immediately creating a barrier.
FinSMEs
16/08/2022